Laura Braun-Parvez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Braun-Parvez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Moulin
Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France
1 shared publication - Françoise Heibel
Department of Nephrology, Dialysis and Transplantation, Strasbourg University Hospital, 1 Place de l’Hopital, BP 426, 67091 Strasbourg, France
1 shared publication - Gabriela Gautier-Vargas
Hop Univ Strasbourg, Serv Nephrol Dialyse Transplantat, 1 Place Hopital, F-67000 Strasbourg, France
1 shared publication - Ilies Benotmane
Department of Nephrology, Dialysis and Transplantation, Strasbourg University Hospitals, France
1 shared publication - Jonas Martzloff
Department of Nephrology, Dialysis and Transplantation, Strasbourg University Hospital, 1 Place de l’Hopital, BP 426, 67091 Strasbourg, France
1 shared publication - Jérôme Olagne
Department of Nephrology, Kidney Transplantation and Hemodialysis, Strasbourg University Hospital, Strasbourg, France
1 shared publication
Latest Publications
- Open Access
- 5 July 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (7) , 1107
Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study
Kidney transplant recipients (KTRs) displays marked inter-individual variations in magnitude of immune responses to anti-SARS-CoV-2 vaccination. The aim of this large single-center study was to identify the predictive factors for serological response to the mRNA-1273 vaccine in KTRs. We also devised a score to optimize prediction with the goal of implementing a personalized vaccination strategy. The study population consisted of 564 KTRs who received at least two doses of the mRNA-1273 vaccine. Anti-RBD IgG titers were quantified one month after each vaccine dose and until six months thereafter. A third dose vaccine was given when the antibody titer after the second dose was p < 0.0001) and the occurrence of a good antibody response (AUC = 0.785, p < 0.0001). Notably, antibody titers declined over time both after the second and third vaccine doses. In summary, a high burden of comorbidities and immunosuppression was correlated with a weaker antibody response. A fourth vaccine dose and/or pre-exposure prophylaxis with monoclonal antibodies should be considered for KTRs who remain unprotected.
- 5 July 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (7) , 1107
Open AccessPrediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study
Kidney transplant recipients (KTRs) displays marked inter-individual variations in magnitude of immune responses to anti-SARS-CoV-2 vaccination. The aim of this large single-center study was to identify the predictive factors for serological response to the mRNA-1273 vaccine in KTRs. We also devised a score to optimize prediction with the goal of implementing a personalized vaccination strategy. The study population consisted of 564 KTRs who received at least two doses of the mRNA-1273 vaccine. Anti-RBD IgG titers were quantified one month after each vaccine dose and until six months thereafter. A third dose vaccine was given when the antibody titer after the second dose was p < 0.0001) and the occurrence of a good antibody response (AUC = 0.785, p < 0.0001). Notably, antibody titers declined over time both after the second and third vaccine doses. In summary, a high burden of comorbidities and immunosuppression was correlated with a weaker antibody response. A fourth vaccine dose and/or pre-exposure prophylaxis with monoclonal antibodies should be considered for KTRs who remain unprotected.